151 related articles for article (PubMed ID: 31569615)
41. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Woods B; Paracha N; Scott DA; Thatcher N
Lung Cancer; 2012 Feb; 75(2):261-7. PubMed ID: 21937141
[TBL] [Abstract][Full Text] [Related]
42. A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Tsumori T; Kawase I
Anticancer Res; 2012 Feb; 32(2):609-13. PubMed ID: 22287752
[TBL] [Abstract][Full Text] [Related]
43. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
44. Current therapies for malignant pleural mesothelioma.
Nakano T
Environ Health Prev Med; 2008 Mar; 13(2):75-83. PubMed ID: 19568885
[TBL] [Abstract][Full Text] [Related]
45. Pemetrexed for diffuse malignant pleural mesothelioma.
Manegold C; Aisner J
Semin Oncol; 2002 Apr; 29(2 Suppl 5):30-5. PubMed ID: 12023790
[TBL] [Abstract][Full Text] [Related]
46. Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
Pasello G; Urso L; Silic-Benussi M; Schiavon M; Cavallari I; Marulli G; Nannini N; Rea F; Ciminale V; Favaretto A
J Thorac Oncol; 2014 Jul; 9(7):1008-1017. PubMed ID: 24922007
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
[TBL] [Abstract][Full Text] [Related]
48. Pemetrexed therapy for malignant pleural mesothelioma.
Puto K; Garey JS
Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
[TBL] [Abstract][Full Text] [Related]
49. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of Src family kinases overcomes anoikis resistance induced by spheroid formation and facilitates cisplatin-induced apoptosis in human mesothelioma cells.
Eguchi R; Fujita Y; Tabata C; Ogawa H; Wakabayashi I; Nakano T; Fujimori Y
Oncol Rep; 2015 Nov; 34(5):2305-10. PubMed ID: 26323315
[TBL] [Abstract][Full Text] [Related]
51. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
52. Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.
Orbaugh KK
Clin J Oncol Nurs; 2004 Jun; 8(3):242-7. PubMed ID: 15208818
[TBL] [Abstract][Full Text] [Related]
53. Current concepts in chemotherapy for malignant pleural mesothelioma.
Sørensen JB
Clin Respir J; 2008 Apr; 2(2):74-9. PubMed ID: 20298310
[TBL] [Abstract][Full Text] [Related]
54. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
55. Malignant pleural mesothelioma: current concepts in treatment.
Tsiouris A; Walesby RK
Nat Clin Pract Oncol; 2007 Jun; 4(6):344-52. PubMed ID: 17534390
[TBL] [Abstract][Full Text] [Related]
56. Cisplatin-Chelated Iminodiacetic Acid-Conjugated Hyaluronic Acid Nanogels for the Treatment of Malignant Pleural Mesothelioma in Mice.
Amano Y; Sakura KL; Ohta S; Ito T
Mol Pharm; 2022 Mar; 19(3):853-861. PubMed ID: 35142223
[TBL] [Abstract][Full Text] [Related]
57. Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells.
Cioce M; Rutigliano D; Puglielli A; Fazio VM
Cancer Drug Resist; 2022; 5(3):814-828. PubMed ID: 36176750
[No Abstract] [Full Text] [Related]
58. Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients.
Affatato R; Mendogni P; Del Gobbo A; Ferrero S; Ricci F; Broggini M; Rosso L
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33419364
[TBL] [Abstract][Full Text] [Related]
59. A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma.
Dell'Anno I; Melani A; Martin SA; Barbarino M; Silvestri R; Cipollini M; Giordano A; Mutti L; Nicolini A; Luzzi L; Aiello R; Gemignani F; Landi S
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626133
[TBL] [Abstract][Full Text] [Related]
60. Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells.
Sato Y; Matsuda S; Maruyama A; Nakayama J; Miyashita T; Udagawa H; Umemura S; Yanagihara K; Ochiai A; Tomita M; Soga T; Tsuchihara K; Makinoshima H
Front Pharmacol; 2018; 9():1129. PubMed ID: 30369878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
